Radiología, Rehabilitación y Fisioterapia
Department


Institute Catalá Oncología
Barcelona, España
Publications in collaboration with researchers from Institute Catalá Oncología (12)
2024
-
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)
Neuro-oncology, Vol. 26, Núm. 11, pp. 2074-2083
2022
-
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
The Lancet Oncology, Vol. 23, Núm. 5, pp. 671-681
-
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
Frontiers in Oncology, Vol. 12
2021
-
10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer
International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77
-
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial
Radiotherapy and Oncology, Vol. 160, pp. 115-119
2020
-
GOECP/SEOR clinical recommendations for lung cancer radiotherapy during the COVID-19 pandemic
WORLD JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Núm. 8
2019
-
Are there enough radiation oncologists to lead the new Spanish radiotherapy?
Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672
2016
-
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial
International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348
2015
-
Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies
Clinical and Translational Oncology, Vol. 17, Núm. 3, pp. 223-229
-
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327
-
Nomogramme für die Prognose eines biochemischen Rezidivs beim Prostatakarzinom nach Strahlentherapie und Androgendeprivationstherapie
Strahlentherapie und Onkologie, Vol. 191, Núm. 10, pp. 792-800